Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase II Study of Docetaxel (T) with or without Capecitabine (X) as Neoadjuvant Chemotherapy in Female Patients with Operable Breast Cancer Who were not Observed Disease Progression after 4 cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) (OOTR N003).

Next Previous
X
Search
Trial Profile

Randomized Phase II Study of Docetaxel (T) with or without Capecitabine (X) as Neoadjuvant Chemotherapy in Female Patients with Operable Breast Cancer Who were not Observed Disease Progression after 4 cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) (OOTR N003).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2018

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
  • Indications Breast cancer
  • Focus Biomarker; Therapeutic Use

    • Most Recent Events

    • 15 Sep 2015 Status changed from active, no longer recruiting to completed as per full results were already published in Pubmed [PMC3825616]
    • 08 Dec 2012 Results presented at the 35th Annual San Antonio Breast Cancer Symposium.
    • 26 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top